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ABSTRACT
This report describes the first occurrence of the
DHA-1 ampC b-lactamase gene in Proteus mirabilis.
The organism was isolated from the vaginal
flora of a pregnant woman in a French hospital.
The DHA-1 b-lactamase gene was identified
on the basis of phenotypic characteristics,
PCR amplification and sequencing. Antagonism
between cefoxitin and the other cephalosporins
suggested inducible production of the DHA-1
enzyme.
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Proteus mirabilis is a Gram-negative bacterium
that is naturally sensitive to ampicillin and
cephalosporins because of the lack of a chromo-
somal ampC b-lactamase gene. However, this
organism can become resistant to ampicillin by
acquisition of a TEM-type penicillinase. Inhibitor-
resistant TEM enzymes and resistance to broad-
spectrum cephalosporins, resulting from the
acquisition of TEM-type extended-spectrum
b-lactamases, have also been described in P. mira-
bilis [1,2]. Most recently, class C b-lactamases,
conferring resistance to 7a-methoxy-cephalospo-
rins, have appeared in this species [3,4]. The ampC
genes described in P. mirabilis belong to the ACC
or CMY families, related to the Hafnia alvei and
Citrobacter freundii ampC chromosomal genes,
respectively, and have been reported to be either
plasmid-encoded or inserted on the chromosome
(probably by transposition) in P. mirabilis [3–6].
The DHA-1 plasmid-encoded ampC gene was first
described in Salmonella enterica in Saudi Arabia
(with recent spread to the UK), and in Klebsiella
pneumoniae [7–11]. The present report describes
the first occurrence of a DHA-1 ampC gene in
P. mirabilis.
The patient concerned was a pregnant woman,
aged 34 years, who was admitted to the maternity
ward of Robert-Debre´ Hospital, Paris. A P. mira-
bilis isolate resistant to cephalothin was isolated
from a vaginal swab taken after 37 weeks of
amenorrhoea. The patient gave birth by Caesarian
section after 40 weeks of amenorrhoea to a healthy
infant that was not colonised by P. mirabilis. Two
days after delivery, the patient had a fever (38.6C)
and was treated with cefotaxime for 3 days, but
with no documented infection (blood and urine
cultures gave negative results). Ten days after
delivery, a P. mirabilis isolate resistant to cephalo-
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thin, together with Pseudomonas aeruginosa, was
isolated from a suppuration of the Caesarian scar.
Local treatment with antiseptic agents was suffi-
cient to cure this superficial infection, and no
antibiotic was given to the patient at that time.
The identification of the organism as P. mirabilis
was by Gram’s stain and tests with the API 20E
and ID32GN systems (bioMe´rieux, Marcy l’Etoile,
France). Antimicrobial susceptibility was tested by
the NCCLS disk diffusion method on Mueller–
Hinton agar (Sanofi-Diagnostics Pasteur, Marnes-
La-Coquette, France). MICs of amoxycillin, cefo-
taxime, ceftazidime, cefepime and imipenem, as
determined by Etests (Biodisk, Solna, Sweden),
were > 256, 0.5, 1.5, 0.064 and 0.25mg ⁄L, respect-
ively. The isolate was resistant to amoxycillin,
cephalothin and amoxycillin–clavulanic acid, but
remained sensitive to ticarcillin, cefotaxime, ceft-
azidime and imipenem. Double-disk diffusion
tests did not indicate synergy between clavulanic
acid and cephalosporins (cefotaxime, ceftazidime,
cefepime), but antagonism between cefoxitin and
the other cephalosporins was observed, thus
suggesting the inducible production of a group
C b-lactamase by this isolate.
Total DNA was extracted with the QIAamp
DNA Mini Kit (Qiagen, Courtaboeuf, France).
PCRs for CMY-2- and ACC-1-like genes were
performed as described previously [3,12], but were
negative. The ampC and ampR genes were ampli-
fied with three pairs of primers generating over-
lapping PCR fragments in a 2243-bp region: DHA
upper1 (5¢-CTCATCCTCCATAAAACAGC-3¢)
and DHA lower1 (5¢-TTATCTCACACCTTTAT-
TACT-3¢); DHA upper2 (5¢-AGATACATTG
CCATTTCCAG-3¢) and DHA lower2 (5¢-ACT-
TGCCGCCGTTACTCACA-3¢); and DHA upper3
(5¢-TGTGCCATCAGCGGTTTATT-3¢) and DHA
lower3 (5¢-TGGAAGGTGAGTGAGTTTTA-3¢).
Sequencing of the PCR products yielded a se-
quence that was 100% identical to the published
sequences of the blaDHA-1 and ampR genes [9]. To
our knowledge, this is the first report of a DHA-1
ampC b-lactamase gene in P. mirabilis.
REFERENCES
1. Mariotte S, Nordmann P, Nicolas MH. Extended-spectrum
beta-lactamase in Proteus mirabilis. J Antimicrob Chemother
1994; 33: 925–935.
2. Bret L, Chanal C, Sirot D, Labia R, Sirot J. Characterization
of an inhibitor-resistant enzyme IRT-2 derived from TEM-
2 beta-lactamase produced by Proteus mirabilis strains.
J Antimicrob Chemother 1996; 38: 183–191.
3. Verdet C, Arlet G, Ben Redjeb S et al. Characterisation of
CMY-4, an AmpC-type plasmid-mediated beta-lactamase
in a Tunisian clinical isolate of Proteus mirabilis. FEMS
Microbiol Lett 1998; 169: 235–240.
4. Decre D, Verdet C, Raskine L et al. Characterization of
CMY-type beta-lactamases in clinical strains of Proteus
mirabilis and Klebsiella pneumoniae isolated in four hospitals
in the Paris area. J Antimicrob Chemother 2002; 50: 681–688.
5. Bret L, Chanal-Claris C, Sirot D et al. Chromosomally
encoded ampC-type beta-lactamase in a clinical isolate of
Proteus mirabilis. Antimicrob Agents Chemother 1998; 42:
1110–1114.
6. Girlich D, Karim A, Spicq C, Nordmann P. Plasmid-
mediated cephalosporinase ACC-1 in clinical isolates of
Proteus mirabilis and Escherichia coli. Eur J Clin Microbiol
Infect Dis 2000; 19: 893–895.
7. Gaillot O, Clement C, Simonet M, Philippon A. Novel
transferable beta-lactam resistance with cephalosporinase
characteristics in Salmonella enteritidis. J Antimicrob Chem-
other 1997; 39: 85–87.
8. Liebana E, Batchelor M, Clifton-Hadley FA et al. First
report of Salmonella isolates with the DHA-1 AmpC beta-
lactamase in the United Kingdom. Antimicrob Agents
Chemother 2004; 48: 4492.
9. Barnaud G, Arlet G, Verdet C et al. Salmonella enteritidis:
AmpC plasmid-mediated inducible beta-lactamase (DHA-
1) with an ampR gene from Morganella morganii. Antimicrob
Agents Chemother 1998; 42: 2352–2358.
10. Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of
conjugative plasmid-mediated AmpC beta-lactamases in
the United States. Antimicrob Agents Chemother 2004; 48:
533–537.
11. Yan JJ, Ko WC, Jung YC, Chuang CL, Wu JJ. Emergence of
Klebsiella pneumoniae isolates producing inducible DHA-1
beta-lactamase in a university hospital in Taiwan. J Clin
Microbiol 2002; 40: 3121–3126.
12. Nadjar D, Rouveau M, Verdet C et al. Outbreak of Klebsi-
ella pneumoniae producing transferable AmpC-type beta-
lactamase (ACC-1) originating from Hafnia alvei. FEMS
Microbiol Lett 2000; 187: 35–40.
592 Clinical Microbiology and Infection, Volume 11 Number 7, July 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 577–596
